

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

.....

Applicants:	Gabor BUTORA et al.	Examiner:	Douglas M. Willis
Serial No.:	10/587,118	Case:	21540P
Filing Date:	July 21, 2006	Art Unit:	1624
For:	AMINOCYCLOPENTYL PYRIDOPYRAZINONE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY		

.....

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Response to Restriction Requirement**

Sir:

In response to the Restriction Requirement that was mailed September 1, 2009, applicants make the following elections:

- Group I is elected.

In response to the requirement for an election of species, the compound of Example 1 is elected as the species.

The species is claimed generically in Claim 1. Formula I as follows:

- E and Z are carbon.
- (A)<sub>0,2</sub> is CH<sub>2</sub>.
- The dotted line in the 5-membered ring in Formula I is absent, so that the bond is a carbon-carbon single bond.
- k and j are 1.
- Y is O.
- R<sup>2b</sup> is the oxygen of a carbonyl.
- R<sup>3</sup> is CF<sub>3</sub>.
- All remaining substituent groups are H or are absent.

Claims 1-24 read on the elected Group I. Claims 1-18 and 20-24 read on the elected species. Claims 25-27 are currently withdrawn.

This is believed to be a complete and timely response to the Restriction Requirement. No fee is believed to be due. If any fee is required, it may be charged to Merck & Co., Inc. Deposit Account No.: 13-2755.

If the Examiner has any questions regarding this response, he is invited to telephone the undersigned attorney at the telephone number below.

Respectfully submitted,

By



James L. McGinnis  
Reg. No. 34,387  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-0641

Date: September 30, 2009